Cubist Systematic Strategies’s Perspective Therapeutics CATX Stock Holding History

Cubist Systematic Strategies’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$194K	Buy	56,696 +43,674	+335%	+$159K	﹤0.01%	2661
2025 Q2	$44.8K	Sell	13,022 -38,458	-75%	-$102K	﹤0.01%	2792
2025 Q1	$110K	Sell	51,480 -209,994	-80%	-$630K	﹤0.01%	2627
2024 Q4	$834K	Buy	+261,474	New	+$2.13M	0.01%	1908
2024 Q2	–	Sell	-52,747	Closed	-$628K	–	3064
2024 Q1	$628K	Buy	+52,747	New	+$450K	﹤0.01%	2488

Other funds holding CATX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cubist Systematic Strategies's CATX Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Perspective Therapeutics (CATX) stake by 335% in Q3 2025, buying an estimated $159K and bringing the position to 56,696 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Cubist Systematic Strategies first reported a position in CATX in Q1 2024 and has held it in 5 quarters since. The position peaked at $834K in Q4 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

Cubist Systematic Strategies held 56,696 shares of Perspective Therapeutics worth $194K as of Q3 2025.
Cubist Systematic Strategies bought 43,674 Perspective Therapeutics shares in Q3 2025, an estimated $159K.
Perspective Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2661 holding.
Cubist Systematic Strategies first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 5 quarters since.
Cubist Systematic Strategies's Perspective Therapeutics position peaked at $834K in Q4 2024.
105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.